만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석
Apixaban versus Warfarin in Patients with Chronic Kidney Disease; A Systematic Review and Meta-analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45-1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events.
Abstract
Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45-1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events.
참고문헌 (37)
- January CT, "2019 AHA", ACC, ACC, pp.HRS Guideline for the Management of Patients With Atrial Fibrillation : A Report of the American College of Cardiology, American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[DOI]
- Pengo V, "Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome : Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome(TRAPS)trial", Lupus, 25(3), pp.301~306 (2016)
- Martin K, "Use of the direct oral anticoagulants in obese patients : guidance from the SSC of the ISTH", J Thromb Haemost, 14(6), pp.1308~1313 (2016)
- Chagnac A, "Glomerular hemodynamics in severe obesity", Am J Physiol Renal Physiol, 278(5), pp.F817~F822 (2000)
- Tobenkin A, "Direct oral anticoagulants and menorrhagia in premenopausal women : data from the food and drug administration adverse event reporting system and US drug utilization", Haemophilia, 23(Suppl 3), pp.43~ (2017)
- Braekkan S, "Obesity and risk of bleeding : the SMART study", J Thromb Haemost, 14(1), pp.65~72 (2016)
- Potpara TS, "Management of atrial fibrillation in patients with chronic kidney disease in clinical practice : a joint European Heart Rhythm Association(EHRA)and European Renal Association", European Dialysis and Transplantation Association(ERA, Europace, pp.2020, 22(3)[DOI]
- "SAVAYSA(TM) oral tablets, edoxaban oral tablets" (2020)[URL]
- Sohal AS, "Uremic bleeding : pathophysiology and clinical risk factors", Thromb Res, 118(3), pp.417~422 (2006)
- Ahuja T, "Oral factor Xa inhibitors versus warfarin for the treatment of venous thromboembolism in advanced chronic kidney disease", Adv Hematol, 2021, pp.8870015~ (2021)
- Ghoshal S, "Mechanisms of stroke in patients with chronic kidney disease", Am J Nephrol, 50(4), pp.229~239 (2019)
- Wattanakit K, "Chronic kidney disease increases risk for venous thromboembolism", J Am Soc Nephrol, 19(1), pp.135~140 (2008)
- Wattanakit K, "Chronic kidney disease increases risk for venous thromboembolism", Curr Opin Pulm Med, 15(5), pp.408~412 (2009)
- Harel Z, "Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD", J Am Soc Nephrol, 25(3), pp.431~442 (2014)
- Amani A, "Safety and efficacy of apixaban use in peritoneal dialysis : A review of the literature", Journal of Pharmacy Technology, 37(3), pp.147~151 (2021)
- "PRADAXA(R) oral capsules, dabigatran etexilate mesylate oral capsules" (2020)[URL]
- "XARELTO(R) oral tablets, rivaroxaban oral tablets" (2020)[URL]
- Parasrampuria DA, "Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa", Clinical pharmacokinetics, 55(6), pp.641~655 (2016)
- Turner RM, "The impact of study size on metaanalyses : examination of underpowered studies in Cochrane reviews", PloS one, 8(3), pp.e59202~ (2013)
- Furlan AD, "2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group", Spine(Phila Pa 1976), 40(21), pp.1660~1673 (2015)
- Herndon K, "Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital", Ann Pharmacother, 54(6), pp.554~560 (2020)
- Reed D, "Safety and effectiveness of apixaban compared to warfarin in dialysis patients", Res Pract Thromb Haemost, 2(2), pp.291~298 (2018)
- Sarratt SC, "Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease", Ann pharmacother, 51(6), pp.445~450 (2017)
- Schafer JH, "Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease", Ann Pharmacother, 52(11), pp.1078~1084 (2018)
- Siontis KC, "Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States", Circulation, 138(15), pp.1519~1529 (2018)
- Stanifer JW, "Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease", Circulation, 141(17), pp.1384~1392 (2020)
- Stanton BE, "Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment", Pharmacotherapy, 37(4), pp.412~419 (2017)
- Konstantinides SV, "2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)", Eur Heart J, 41(4), pp.543~603 (2020)
- Lee CH, "Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran", Int J Cardiol, 228, pp.771~778 (2017)
- 안상준, "Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update", 대한뇌졸중영문학회지, 19(1), pp.3~10 (2017), 대한뇌졸중학회
- Chokesuwattanaskul R, "Safety and efficacy of apixaban versus warfarin in patients with endstage renal disease : Meta-analysis", Pacing Clin Electrophysiol, 41(6), pp.627~634 (2018)
- Hafez M. Abdullah, "Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis", Cardiovascular Revascularization Medicine, 30, pp.26~32 (2021), Elsevier BV[DOI]
- Hanni C, "Outcomes associated with apixaban vs warfarin in patients with renal dysfunction", Blood Advances, 4(11), pp.2366~2371 (2020)
- Ionescu F, "Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?", Eur J Haematol, 106(5), pp.689~696 (2021)
- "Stroke and Major Bleeding when Switching from Warfarin to Apixaban in Patients with Advanced Chronic Kidney Disease and Prevalent Atrial Fibrillation"[URL]
- Cho MS, "Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing", Am J Cardiol, 125(9), pp.1332~1338 (2020)
- Labovitz AJ, "Early apixaban use following stroke in patients with atrial fibrillation : Results of the AREST trial", Stroke, 52(4), pp.1164~1171 (2021)